Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS

ABSTRACT

Objective: Our objective was to determine whether altered naive CD4 T-cell biology contributes to development of disease progression in secondary progressive multiple sclerosis (SPMS).

Methods: We compared the naive CD4 T-cell gene expression profiles of 19 patients with SPMS and 14 healthy controls (HCs) using a whole-genome microarray approach. We analyzed surface protein expression of critical genes by flow cytometry after T-cell receptor (TCR) stimulation of naive CD4 T cells isolated from HCs and patients with SPMS.

Results: Hierarchical clustering segregated patients with SPMS into 2 subgroups: SP-1, which had a short duration of relapsing-remitting multiple sclerosis (MS), and SP-2, which had a long duration of relapsing-remitting MS. SP-1 patients upregulated numerous immune genes, including genes within TCR and toll-like receptor (TLR) signaling pathways. SP-2 patients showed immune gene downregulation in comparison with HCs. We identified an SP-1–specific transcriptional signature of 3 genes (TLR4, TLR2, and chemokine receptor 1), and these genes had higher surface protein expression in SP-1 than in SP-2. After TCR stimulation for 48 hours, only SP-1 showed a progressive linear increase in TLR2 and TLR4 protein expression.

Conclusions: Differences in naive CD4 T-cell biology, notably of TCR and TLR signaling pathways, identified patients with MS with more rapid conversion to secondary progression, a critical determinant of long-term disability in MS.
T-cell receptor (TCR) and toll-like receptor (TLR) signaling pathways, compared with controls and SP-2 patients. Surface marker analyses before and after TCR stimulation confirmed naive T-cell immune activation in SP-1 patients. Thus, differences in naive CD4 T-cell biology identify patients with MS having different rates of development of secondary progression, the critical determinant of long-term prognosis in MS.6

**METHODS** Patients and controls. We recruited 19 patients with SPMS, 5 with primary progressive MS (PPMS), and 13 with RRMS from the Montreal Neurological Hospital MS Clinics, diagnosed by standard criteria, and 14 HCs (table 1). Inclusion criteria were females, age younger than 65 years, and Expanded Disability Status Scale (EDSS) score <7 for patients with progressive MS. Exclusion criteria included autoimmune diseases other than MS, relapses or treatment with immunomodulatory agents, cytotoxic agents, or corticosteroids within 3 months, or other than MS, relapses or treatment with immunomodulatory agents, cytotoxic agents, or corticosteroids within 3 months, or any infection in the previous 4 weeks. Initially, we analyzed only female HCs and patients with SPMS by microarrays, because of male-female differences in gene expression.8 Subsequently, we included patients with RRMS and PPMS in microarray studies to determine the stability of microarray-defined SPMS subgroups. For protein expression studies, we recruited additional patients with SPMS, based on RRMS durations.

**Standard protocol approvals, registrations, and patient consents.** The Institutional Review Board of McGill University, Montreal, provided ethical approval. All participants provided written informed consent.

**Naive CD4 T-cell isolation, RNA preparation, and hybridization.** We isolated peripheral blood CD4+CD45RA- (naive CD4) T cells by negative selection using MACS naive CD4 T-cell isolation kits, human II (Miltenyi Biotec, Bergisch Gladbach, Germany). We isolated total RNA using RNeasy Plus Mini Kits (Qiagen, Mississauga, Canada), amplified the RNA using Low RNA Input Linear Amplification Kit PLUS (Agilent Technologies, Mississauga, Canada), dye-labeled (Cy5) and hybridized on 4×44 K Oligochip Slides (Agilent Technologies) containing 41,000 unique probes. We used the Agilent 2100 Bioanalyzer to verify RNA quality.

**Array data quality and analysis.** We analyzed microarray data using GeneSpring GX (version 11, Agilent Technologies) and R programs.9,10 We used Feature Extraction QC reports (FE 9.3.1, Agilent Technologies) to control RNA quality and applied LOWESS (locally weighted scatterplot smoothing) normalization. Using analysis of variance (ANOVA), we identified the most variable genes across SPMS and HC samples followed by unsupervised hierarchical clustering11 to identify sample subgroups. To identify differentially expressed genes between subgroups, we used GeneSpring GX, including multiple testing correction, Benjamini-Hochberg false discovery rate (FDR)-corrected p value ≤0.05, together with an absolute difference ≥1.7-fold and 1.3-fold in mean intensity for each gene. We did not use more stringent FDR or fold changes because these may overlook subtle but important pathway changes in complex diseases such as MS.11 We performed in-depth pathway analysis with GeneSpring GX, Gene Ontology, Ingenuity Pathway Analysis, and Gene Set

**Table 1** Cohorts for microarray studies

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>PPMS (n = 5)</th>
<th>SPMS (n = 19)</th>
<th>SP-1 (n = 6)</th>
<th>SP-2 (n = 13)</th>
<th>RRMS (n = 13)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y (SD)</td>
<td>57 (4.5)</td>
<td>56.8 (6.6)</td>
<td>52.5 (9.1)</td>
<td>57.9 (3.99)</td>
<td>40.33 (9.03)</td>
<td>0.22</td>
</tr>
<tr>
<td>Age at MS onset, y (SD)</td>
<td>47 (5.3)</td>
<td>27.9 (7.3)</td>
<td>30.5 (10.2)</td>
<td>26.5 (5)</td>
<td>—</td>
<td>0.41</td>
</tr>
<tr>
<td>Age at SPMS onset, y (SD)</td>
<td>49.3 (8.4)</td>
<td>42.8 (11.1)</td>
<td>50.8 (3.9)</td>
<td>—</td>
<td>0.148</td>
<td></td>
</tr>
<tr>
<td>Total MS duration, y (SD)</td>
<td>10 (1.6)</td>
<td>28.9 (8.5)</td>
<td>21.8 (5.2)</td>
<td>31.4 (7.5)</td>
<td>15.1 (5.17)</td>
<td>0.008</td>
</tr>
<tr>
<td>SPMS duration, y (SD)</td>
<td>7.7 (6.6)</td>
<td>9.67 (4.2)</td>
<td>7.2 (5.2)</td>
<td>—</td>
<td>0.303</td>
<td></td>
</tr>
<tr>
<td>RRMS duration, y (SD)</td>
<td>20.9 (7)</td>
<td>12.17 (2.23)</td>
<td>24.27 (3.69)</td>
<td>15.1 (5.17)</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>EDSS median score</td>
<td>6</td>
<td>6</td>
<td>5.75</td>
<td>6.25</td>
<td>1</td>
<td>0.957</td>
</tr>
<tr>
<td>EDSS median score, SPMS onset</td>
<td>3.75</td>
<td>4</td>
<td>3.5</td>
<td>—</td>
<td>0.947</td>
<td></td>
</tr>
<tr>
<td>Relapses during RRMS phase, mean (SD)</td>
<td>1.83 (1.47)</td>
<td>2.38 (2.14)</td>
<td>1.2 (1.2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapses during SPMS phase, n</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval from relapse/treatment and blood draw, y (SD)</td>
<td>9.83 (6.6)</td>
<td>10.96 (7.4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CIS symptoms, n

| Motor 1, sensory 2, ON 3 | Motor 1, sensory 4, ON 1, sensory motor 7 |

Abbreviations: CIS = clinically isolated syndrome; EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; ON = optic neuritis; PPMS = primary progressive MS; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS. Progressive MS is divided into SPMS and PPMS subgroups, and SP-1 and SP-2 are subgroups of SPMS. Except for EDSS scores, mean values are shown. All p values are for comparisons between SP-1 and SP-2 patients using Student t test for ages and MS durations and Mann-Whitney test for EDSS scores. Healthy controls (n = 14), mean age ± SD (54.7 ± 6.7). Healthy controls and total SPMS group patients did not differ in ages (p = 0.61). None of the 13 patients with RRMS had a relapse in the previous 5 years. In the SP-1 subgroup, one patient had methotrexate treatment during the RRMS phase. No other patient had immunomodulatory/immunosuppressive treatment during either RRMS or SPMS phases.
Enrichment Analysis (GSEA).13,14 For GSEA, we used an FDR <0.25, as recommended.15

Real-time PCR. We used real-time PCR to confirm the expression of selected genes (see the results section) using the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA) and the comparative C2 method.15

Surface marker expression and functional analyses. We analyzed naive CD4 T-cell surface markers before and after in vitro culture of isolated naive CD4 T cells in flat-bottom plates (250 x 10^5 T cells/well), with and without CD3/CD28 Dynabeads human T-activator CD3/CD28 (Invitrogen, Grand Island, NY), under optimal stimulation conditions (25 µL beads/10^6 naive CD4 T cells) for 24 and 48 hours in complete RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin/streptomycin in 5% CO2 at 37°C. We used a FACSAria (Becton Dickinson, San Diego, CA) to analyze T-cell aliquots stained with the following antibodies: CD45RA PE-Cy7, TLR2 PE, TLR4 APC, CD28 PerCP-Cy 5.5 (eBioscience, San Diego, CA), and CCR1 Alexa Fluor 488 (R&D Systems, Minneapolis, MN). We defined CD4+ CD45RA+ CD45RO- CD62L+ T cells as naive. Purity was >90% in all samples, with the majority >95%.

Statistics. Using GraphPad Prism 5 and the D’Agostino-Pearson omnibus test, we determined whether data had a normal distribution. We used the Student t test to analyze ages and MS durations, and the Mann-Whitney test to analyze EDSS scores, because the EDSS does not have a normal distribution. We analyzed surface protein expression data using FlowJo 7.6.4 and compared percent expression between HCs and 2 SPMS subgroups using 1-way ANOVA. We compared median fluorescence intensity (MFI) between subgroups using Kruskal-Wallis and Dunn multiple comparison tests. To compare temporal changes within subgroups, we used Friedman and Dunn posttests for mean fluorescence intensity (MFI). We used repeated-measures ANOVA plus Tukey multiple comparison test and an ANOVA posttest for linear trends to compare percent expression. A p value ≤0.05 was considered statistically significant. We used Pchiptest14 to confirm reproducibility of microarray-defined clusters.

RESULTS Hierarchical clustering discriminated HCs from SPMS and identified 2 SPMS subgroups: Association of subgroups with RRMS duration. Unsupervised hierarchical clustering (Ward clustering method and Euclidean distance metric) based on 1,439 genes having the greatest variance across all HCs and patients with SPMS segregated HCs and patients with SPMS from one another (figure 1). Notably, we identified 2 SPMS subgroups, which we termed SP-1 and SP-2. Pvclust, a multiscale bootstrap resampling method, gave an “approximately unbiased” p value of 0.95, indicating that all subgroups are significantly reproducible16 and not due to random partitioning of samples.

In a limited study, we investigated whether the segregation of patients with SPMS into subgroups was temporally stable. We repeated microarray analyses for one SP-1 and one SP-2 patient on peripheral blood samples taken 11 and 6 months after the initial blood draws. Hierarchical clustering using the most variable genes across all samples segregated the 2 patients as found previously (data not shown). That is, the gene expression differences between patients with SPMS seem stable over time.

Patients in the SP-1 and SP-2 subgroups did not differ in mean ages, EDSS scores, age at onset, or mean SPMS durations. Interestingly, SP-1 patients had a shorter mean RRMS duration than SP-2 patients (12.17 vs 24.27 years; p < 0.001). These differences in RRMS duration explain the shorter total mean MS duration in SP-1 vs SP-2 (21.8 vs 31.4 years, p = 0.008) (table 1).

Transcriptional program associated with T-cell activation in SP-1. We found significant differences in gene expression between HCs and total SPMS (data not shown), between HCs and the 2 SPMS subgroups, and between SP-1 and SP-2. SP-1 upregulated most differentially expressed genes between SP-1 and HCs (1,901 upregulated, 100 downregulated, FDR-corrected p ≤ 0.05, ±1.7-fold change), and most genes were immune-related. SP-2 downregulated most differentially expressed genes between SP-2 and HCs, and few genes were immune-related (figure e-1 on the Neurology® Web site at www.neurology.org). SP-1 upregulated most differentially expressed genes between SP-1 and HCs (1,901 upregulated, 100 downregulated, FDR-corrected p ≤ 0.05, ±1.7-fold change).

Comparisons of SP-1 vs HCs and SP-1 vs SP-2 showed that approximately 40% and 70% of the differentially expressed genes in SP-1 overlapped with a T-cell activation signature obtained by TCR stimulation of CD4 T cells.17 That is, many genes upregulated during T-cell activation17,18 had increased expression in SP-1 vs both HCs and SP-2: upregulated genes included proapoptotic genes CASP1 (1.8× up) and FAS (1.8× up), chemokine receptors CCR1 (7.3× up) and CCR2 (4.8× up), and ILIR2 (4.8× up) (table e-1A). TOB1, a gene with reduced expression in patients with CIS having rapid conversion to RRMS,3 was downregulated in SP-1 vs SP-2 (FDR = 6.6E-4, 1.4× down).

We compared patients with stable RRMS with HCs and our now-defined SP-1 and SP-2 subgroups to see whether the patients with RRMS differed from our SPMS subgroups. SP-1 and SP-2 patients continued to represent separate clusters (data not shown). We questioned whether SP-2 patients upregulated genes involved in neurodegeneration. GSEA showed no altered expression of genes in neurodegeneration pathways, in keeping with recent findings from genome-wide association studies.19

Altered expression of genes involved in TCR and TLR signaling in SP-1. Several tyrosine kinase genes involved in TCR-induced signaling (including LYN, 7.2× up; ZAP70, 1.3× down; and SYK, 4.3× up)
and genes involved in calcium signaling (table e-1B) had altered expression in SP-1 vs HCs. The vitamin D receptor (VDR), normally expressed on naive CD4 T cells only after TCR signaling, showed increased gene expression in SP-1 vs HCs (FDR = 1.7E-7, 3.8 up). Cells of the innate immune system, as well as activated and memory T cells, express TLRs. Normally, naive CD4 T cells express very low levels of TLR messenger RNA but TCR signaling upregulates TLR expression. TLR-2 is a costimulatory receptor for TCR activation and TLR-4 induction regulates TCR signaling events through the mitogen-activated protein kinase (MAPK) cascade. TLR1, TLR2, TLR4, and TLR7 (FDR <1E-5; 2X, 4.2X, 8.1X, and 6X up, respectively) were among the genes showing the highest expression in SP-1 vs HCs (table e-1B). SP-1 patients upregulated many downstream targets of TLR signaling including MYD88, IRF5, IRF7, TANK (TRAF family member-associated NF-κB activator), TBK1, and MAPK. Thus, our pathway analyses suggest that enhanced TLR-TCR signaling results in increased activation of naive CD4 T cells in SP-1.

T-cell activation transcriptional signatures define SP-1 patients. Using Gene Ontology, GSEA, and Ingenuity Pathway Analysis, we generated a gene list of 130 T-cell activation-associated genes and performed unsupervised hierarchical clustering of all HCs and patients with SPMS and RRMS. We included 5 patients with PPMS in this comparison to determine whether this gene list is SP-1–specific. SP-1 patients segregated from all other individuals (data not shown). Comparison of this 130-gene list with the gene set in reference 5 identified TOB1 as the only gene overlapping with our dysregulated pathways. From the 130-gene list, we selected 3 genes (TLR2, TLR4, and CCR1) because...
their expression levels (figure 2A) suggested that they could be used for further microarray studies and for protein expression analyses; unlike most genes in the list, these genes had corresponding T-cell surface membrane products recognized by commercially available monoclonal antibodies. Real-time PCR confirmed the relative upregulation of the 3 genes in SP-1 (data not shown). Unsupervised hierarchical clustering using this 3-gene list segregated SP-1 patients from all other individuals (figure 2B), indicating that this 3-gene list is SP-1–specific and suggests that HCs, SP-2 patients, patients with stable RRMS, and patients with PPMS have similar low levels of naive T-cell activation.

Naive CD4 T-cell surface markers before and after CD3/CD28 stimulation. Initially, to confirm gene expression results at the protein expression level,
we analyzed naïve CD4 T-cell surface expression of the 3 SP-1 signature genes (TLR2, TLR4, and CCR1), before and after anti-CD3/CD28 stimulation. We also studied surface expression of the CD28 costimulatory molecule. We included 3 SP-1 and 2 SP-2 patients from our initial microarray studies (bled approximately 2 years later). We recruited 2 new SP-1 patients, 3 new SP-2 patients, and 5 HCs. The 5 SP-1 and 5 SP-2 patients had respective RRMS durations of <11 years and >20 years (table 2). In SP-1, freshly isolated naïve CD4 T cells had significantly higher percentage of TLR2, TLR4, and CCR1 expression than SP-2 and HCs (figure 3A). Because monocytes have high TLR expression, we contain naïve CD4 T cells for CD14, a monocyte/macrophage marker, and for CD4, CD45RA, TLR2, and TLR4 before and after 24 hours of stimulation with Dynabeads. The percentage of CD14 expression varied from 0% to 0.125%, with no CD14 expression on TLR2- or TLR4-positive cells, i.e., TLR positivity does not reflect monocyte contamination. Thus, these surface marker studies confirm our microarray findings at the protein expression level.

After TCR stimulation, TLR2 and TLR4 expression (MFI and %) peaked at 24 hours in HCs and the SP-2 subgroup and then decreased to prestimulation levels by 48 hours, whereas TLR2 and TLR4 expression increased linearly in SP-1 from 0 to 24 to 48 hours; at 48 hours, these TLRs had higher expression levels by 48 hours, whereas TLR2 and TLR4 expressed SP-2 (figure 3, B and C). The increasing TLR expression in SP-1 after TCR stimulation supports our microarray data and suggests that question, a larger prospective study focusing on RRMS is needed. Our data suggest that naive CD4 T-cell upregulation/T-cell activation identifies patients with MS having a short vs protracted RRMS course. The downregulation of TOB1 in SP-1 vs

**DISCUSSION** We report that differences in naïve CD4 T-cell biology, identified by unsupervised hierarchical clustering, segregated patients with SPMS into 2 significantly reproducible subgroups. We did not preselect patients on the basis of their RRMS durations for these gene expression studies, but these durations differed significantly between subgroups (SP-1 vs SP-2; 12.17 vs 24.27 years). One question is whether patients with RRMS would also separate into 2 distinct subgroups, but to address that question, a larger prospective study focusing on RRMS is needed. Our data suggest that naïve CD4 T-cell upregulation/T-cell activation identifies patients with MS having a short vs protracted RRMS course. The downregulation of **TOB1** in SP-1 vs

---

**Table 2** Cohorts for surface protein expression analysis

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>HCs (n = 5)</th>
<th>SPMS (n = 10)</th>
<th>SP-1 (n = 5)</th>
<th>SP-2 (n = 5)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y (SD)</td>
<td>52.4 (7)</td>
<td>54.1 (7.4)</td>
<td>49.2 (6.87)</td>
<td>59 (3.8)</td>
<td>0.07</td>
</tr>
<tr>
<td>Total MS duration, y (SD)</td>
<td>—</td>
<td>28.78 (9.12)</td>
<td>20.33 (6.03)</td>
<td>33 (7.38)</td>
<td>0.051</td>
</tr>
<tr>
<td>SPMS duration, y (SD)</td>
<td>—</td>
<td>8.25 (4.71)</td>
<td>11.67 (3.51)</td>
<td>6.2 (4.32)</td>
<td>0.109</td>
</tr>
<tr>
<td>RRMS duration, y (SD)</td>
<td>—</td>
<td>17.5 (9.35)</td>
<td>9.4 (2.07)</td>
<td>25.6 (5.32)</td>
<td>0.001</td>
</tr>
<tr>
<td>EDSS median score</td>
<td>—</td>
<td>6.5</td>
<td>6.75</td>
<td>6.5</td>
<td>0.695</td>
</tr>
<tr>
<td>RRMS relapses, mean (SD)</td>
<td>4.6 (3.2)</td>
<td>4.4 (3.3)</td>
<td>4.8 (3.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SPMS relapses, n</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interval from relapse or treatment and blood draw, y (SD)</td>
<td>7.6 (5.0)</td>
<td>6.8 (5.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: EDSS = Expanded Disability Status Scale; HC = healthy control; MS = multiple sclerosis; RRMS = relapsing-remitting MS; SPMS = secondary progressive MS. SP-1 and SP-2 are subgroups of SPMS. Except for EDSS, mean values are shown. All p values are for comparisons between SP-1 and SP-2 patients using Student t test for ages and MS durations and Mann-Whitney test for EDSS scores. One SP-1 patient received interferon beta-1a and then interferon beta-1b during SPMS, 2 years before blood draw, and one SP-1 patient received cyclophosphamide and interferon beta-1b during RRMS and then interferon beta-1b during the SPMS phase 14 years before blood draw. One SP-2 patient received interferon beta-1b during SPMS, 4 years before blood draw.
Figure 3  Surface expression of 3-gene signature and CD28

[A] Increased protein expression on freshly isolated naive CD4 T cells from SP-1. SP-1 patients had significantly higher percentage of TLR2, TLR4, and CCR1 than HCs and SP-2 patients (95% confidence interval not shown) and higher TLR4 MFI than HCs and SP-2 patients ($p < 0.05$, both comparisons). (B) TCR stimulation increased TLR2 surface expression in SP-1. At 48 hours, SP-1 had increased percentage of TLR2 and MFI ($p < 0.05$, both comparisons) compared with unstimulated cells, with a positive linear increase in percentage of TLR2 from 0 to 48 hours ($p = 0.02$). At 48 hours, SP-1 had higher percentage of TLR2 expression than HCs and SP-2 ($p < 0.001$, both comparisons) and higher TLR2 MFI than HCs and SP-2 ($p < 0.05$, both comparisons). (C) TCR stimulation increased TLR4 surface expression in SP-1. The percentage of TLR4 increased in HCs ($p < 0.05$) and SP-2 ($p < 0.01$) from 0 to 24 hours, then decreased from 24 to 48 hours. In SP-1, percentage TLR4 showed a positive linear increase from 0 to 48 hours ($p = 0.0025$). At 48 hours, SP-1 had higher percentage of TLR4 than HCs or SP-2 ($p < 0.01$, both comparisons) and higher TLR4 MFI than HCs or SP-2 ($p < 0.05$, both comparisons). (D) CD28 surface expression. TCR stimulation for 24 hours decreased percentage CD28 ($p < 0.001$) and CD28 MFI ($p < 0.05$, not shown) in all groups, but at 24 hours, SP-1 had higher percentage CD28 than HCs ($p < 0.05$) or SP-2 ($p < 0.01$) plus higher CD28 MFI than HCs ($p < 0.05$, not shown). HC = healthy control; MFI = mean or median fluorescence intensity; TCR = T-cell receptor.
SP-2 supports this interpretation, as this repressor of naive CD4 T-cell activation is downregulated in patients with CIS having rapid progression to RRMS.\(^5\) Possibly, TOB1 downregulation persists from CIS to RRMS to SPMS and identifies patients with rapid MS progression. Some researchers suggest that a short RRMS phase predicts rapid disease progression in SPMS.\(^5\) Thus, SP-1 patients could potentially have a more active/aggressive SPMS disease course.

The upregulation of genes involved in TCR and TLR signaling in SP-1 is noteworthy as various TLRs function as costimulatory receptors that can enhance proliferation and cytokine production by TCR-activated T cells.\(^21,22\) Gandhi et al.\(^26\) reported T-cell dysregulation in all MS subtypes. Our findings modify this conclusion by showing, at least for naïve CD4 T cells, that only a subgroup of patients with SPMS has immune gene dysregulation. Moreover, the findings suggest either global naïve CD4 T-cell activation in SP-1 or activation of sufficient naïve CD4 T cells to permit detection of differences between patient subgroups. Of interest is the basis of the immune gene dysregulation in SP-1. Some claim a link between homeostatic T-cell proliferation and autoimmunity.\(^3,4\) We previously reported reduced thymic output with increased homeostatic naïve CD4 T-cell proliferation in RRMS.\(^5,27,28\) Possibly, SP-1 patients had increased homeostatic proliferation but we have no data on this issue.

A potential limitation of our study is that we did not repeat the microarray study to validate our gene expression findings. Instead, we opted to study the protein expression of the 3-gene signature on 2 separate cohorts of HCs and patients with SPMS. The significantly increased TLR2, TLR4, and CCR1 expression on freshly isolated naïve CD4 T cells in SP-1 is consistent with the findings of an activated transcriptional program in this patient subgroup. The differences in TLR expression between subgroups seem to be small, but are entirely consistent with another report that demonstrated biologically significant differences in T-cell TLR expression between patients and controls.\(^29\) The progressive linear increase in TLR expression under optimal stimulation conditions provides further evidence of T-cell activation in SP-1. CD28 stimulation transiently downregulates CD28 messenger RNA and surface expression levels in CD4 T cells, with resulting temporary unresponsiveness to CD28 signaling.\(^50\) The decrease in TLR protein levels from 24 to 48 hours in HCs and SP-2 may reflect a normal feedback response to TCR signaling due to loss of CD28. Conversely, the relative CD28 retention in SP-1 at the 24-hour time point may have permitted a continued naïve CD4 T-cell response to TCR signaling, leading to a sustained increase in TLR protein expression. Together, the microarray and surface phenotypic marker findings suggest in vivo naïve CD4 T-cell activation in SP-1 patients and that this activation is responsible for the increased response to in vitro TCR signaling seen in these patients. Microarray-based classification has predictive value in CIS\(^5\) and MS.\(^35\) For example, T-cell transcriptional profiling can predict the response to interferon β (IFNβ) treatment in RRMS.\(^52\) Our microarray findings have potential clinical implications for SPMS. The global naïve CD4 T-cell downregulation in SP-2, i.e., in the larger SPMS subgroup, suggests that patients with this phenotype will be unresponsive to anti-inflammatory treatments. A North American SPMS trial showed no reduction in disability progression with IFNβ treatment.\(^35\) In a European trial, which included younger patients with shorter disease duration, higher relapse rate, and more aggressive SPMS, some patients showed reduced disability progression.\(^34,35\) The patients who benefited from IFNβ treatment may correspond, in part, to our SP-1 subgroup with T-cell activation and rapid progression. Thus, our 3-gene T-cell activation signature may identify patients with SPMS who would benefit from anti-inflammatory therapies, but further validation of this signature is indicated.

**AUTHOR CONTRIBUTIONS**

E. Zasteps, PhD graduate student: designed, optimized, and performed the cell isolation, microarray experiments, real-time PCR experiments, array quality control, and data analysis; performed the protein expression and T-cell activation experiments and data analysis; critically interpreted the data and wrote the majority of the manuscript. L. Fitz-Gerald, MS student: participated in patient recruitment; critically evaluated, discussed, and corrected the manuscript; helped with protein expression experiments. M. Hallett, bioinformaticist: actively participated in discussion of class discovery and class distinction methods, including appropriate usage of p-value to evaluate unbiased hierarchical clustering, involved extensively in discussion and evaluation of data, and critically evaluated and discussed the manuscript. J. Antel, A. Bar-Or, and Y. Lapierre, neurologists with expertise in MS: reviewed and selected patients with MS who satisfied the currently accepted diagnostic criteria and the requirements for recruitment into the study, provided relevant clinical data, critically evaluated and discussed the data and data interpretation, and discussed the manuscript and review. S. Baranini, human genomics expert: provided microarray data from previous study identifying TOB1 as a predictive marker of CIS disease progression, facilitated comparison of our data set with his with insights into the relevance of TOB1 in our progressive MS study, and provided a helpful and critical review of the manuscript. D.G. Haegert, principal investigator and supervisor of this research: intimately involved in experimental design, writing of the manuscript, discussion and interpretation of the data, communication and discussion with neurologists, and extensive involvement in manuscript revisions.

**ACKNOWLEDGMENT**

The authors thank Julie Livingstone (McGill University, Montreal, Canada) for her input on the microarray analysis and Dr. Maria Cortes (Montreal Neurological Hospital, Montreal, Canada) for her assistance with the clinical data analysis. The authors also thank the patients with MS and healthy controls who participated in this study.
STUDY FUNDING
Supported by the Multiple Sclerosis Society of Canada. E.Z. was funded by a PhD fellowship from NSERC. The authors acknowledge infrastructure support and technical assistance from the Breast Cancer Functional Genomics Group, which is supported by funds from the Terry Fox Foundation and CIHR.

DISCLOSURE
E. Zastepa, L. Fitz-Gerald, and M. Hallen report no disclosures. J. Antel (* = compensation received) reports the following disclosures: Commercial: advisory boards or data safety monitoring committees: Biogen Idec*, TEVA*, emdSerono*, Genzyme*, Sanofi-Aventis*, Novartis*, nonprofi; advisory boards or data safety monitoring committees: Cleveland Clinic Foundation®, MS Society (Canada). MSIF, GlaxoSmithKline Research Foundation (USA), Herie Foundation (Germany®), Burbrogh Wellcome Medical Scientist Programme. Editorial: editor for the Americas Multiple Sclerosis Journal (SAGE Publishing®). Research support: MS Society of Canada, CIHR (Industry Partnership Program), Novartis. A. Bar-Or has participated as a speaker at meetings sponsored by, received consulting fees and/or received grant support from: Amgenimmune, Bayhill Therapeutics, Belles/Bayer, Biogen Idec, BioMS, DiaGenas, Eli Lilly, Genentech, GlassSmithKline, Guthy-Jackson/GGF, Merck/EMD Serono, Meidimmune, Mitsubishi Pharma, Novartis, Ono Pharma, Receptors, Roche, Sanofi-Genzyme, Teva Neuroscience, Wyeth. S. Baranzini reports no disclosures. Y. Lapierre has received consulting fees and serves on advisory boards from Biogen Idec, Bayer, EMD Serono, Genzyme, Novartis, Teva. D. Haegert reports no disclosures. Go to Neurology.org for full disclosures.

Received June 4, 2013. Accepted in final form November 12, 2013.

REFERENCES


This Week’s Neurology® Podcast

Summary of evidence-based guideline update: Prevention of stroke in nonvalvular atrial fibrillation (See p. 716)

This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the February 25, 2014, issue of Neurology. In the second segment, Dr. Brett Kissela talks with Dr. Gary Gronseth about the AAN paper on prevention of stroke in nonvalvular atrial fibrillation. Dr. James Addington reads our e-Pearl of the week about superficial siderosis. In the next part of the podcast, Dr. Andy Southerland focuses his interview with Dr. Seemant Chaturvedi on Edoxaban, non-pharmaceutical options for stroke prevention in afib: ablation, atrial appendage occluder devices, and any other options. Disclosures can be found at www.neurology.org.

At www.neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent podcast and subscribe to the RSS feed.

CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category 1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.

Neurology® Launches Subspecialty Alerts by E-mail!

Customize your online journal experience by signing up for e-mail alerts related to your subspecialty or area of interest. Access this free service by visiting http://www.neurology.org/site/subscriptions/etoc.xhtml or click on the “E-mail Alerts” link on the home page. An extensive list of subspecialties, methods, and study design choices will be available for you to choose from—allowing you priority alerts to cutting-edge research in your field!
Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS
Evelyn Zastepa, Leslie Fitz-Gerald, Michael Hallett, et al.

*Neurology* 2014;82;681-690 Published Online before print January 22, 2014
DOI 10.1212/WNL.0000000000000146

This information is current as of January 22, 2014
<table>
<thead>
<tr>
<th><strong>Updated Information &amp; Services</strong></th>
<th>including high resolution figures, can be found at: <a href="http://n.neurology.org/content/82/8/681.full">http://n.neurology.org/content/82/8/681.full</a></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Supplementary Material</strong></td>
<td>Supplementary material can be found at: <a href="http://n.neurology.org/content/suppl/2014/01/22/WNL.0000000000000146.DC1">http://n.neurology.org/content/suppl/2014/01/22/WNL.0000000000000146.DC1</a></td>
</tr>
<tr>
<td><strong>References</strong></td>
<td>This article cites 32 articles, 11 of which you can access for free at: <a href="http://n.neurology.org/content/82/8/681.full#ref-list-1">http://n.neurology.org/content/82/8/681.full#ref-list-1</a></td>
</tr>
<tr>
<td><strong>Citations</strong></td>
<td>This article has been cited by 1 HighWire-hosted articles: <a href="http://n.neurology.org/content/82/8/681.full#otherarticles">http://n.neurology.org/content/82/8/681.full#otherarticles</a></td>
</tr>
<tr>
<td><strong>Subspecialty Collections</strong></td>
<td>This article, along with others on similar topics, appears in the following collection(s):</td>
</tr>
<tr>
<td></td>
<td><strong>All Clinical Neurology</strong> <a href="http://n.neurology.org/cgi/collection/all_clinical_neurology">http://n.neurology.org/cgi/collection/all_clinical_neurology</a></td>
</tr>
<tr>
<td></td>
<td><strong>All Demyelinating disease (CNS)</strong> <a href="http://n.neurology.org/cgi/collection/all_demyelinating_disease_cns">http://n.neurology.org/cgi/collection/all_demyelinating_disease_cns</a></td>
</tr>
<tr>
<td></td>
<td><strong>Autoimmune diseases</strong> <a href="http://n.neurology.org/cgi/collection/autoimmune_diseases">http://n.neurology.org/cgi/collection/autoimmune_diseases</a></td>
</tr>
<tr>
<td></td>
<td><strong>Gene expression studies</strong> <a href="http://n.neurology.org/cgi/collection/gene_expression_studies">http://n.neurology.org/cgi/collection/gene_expression_studies</a></td>
</tr>
<tr>
<td></td>
<td><strong>Multiple sclerosis</strong> <a href="http://n.neurology.org/cgi/collection/multiple_sclerosis">http://n.neurology.org/cgi/collection/multiple_sclerosis</a></td>
</tr>
<tr>
<td><strong>Errata</strong></td>
<td>An erratum has been published regarding this article. Please see next page or: <a href="http://n.neurology.org/content/82/13/1193.2.full.pdf">http://n.neurology.org/content/82/13/1193.2.full.pdf</a></td>
</tr>
<tr>
<td><strong>Permissions &amp; Licensing</strong></td>
<td>Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a></td>
</tr>
<tr>
<td><strong>Reprints</strong></td>
<td>Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a></td>
</tr>
</tbody>
</table>

*Neurology* © is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2014 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.
ANTITHROMBOTIC DRUGS AND RISK OF HEMORRHAGIC STROKE IN THE GENERAL POPULATION

Simone Vidale, Como, Italy: Garcia-Rodriguez et al. examined the risk of hemorrhagic stroke in patients treated with antithrombotics. While warfarin increased the risk of both intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), aspirin did not influence the risk of ICH and surprisingly decreased the frequency of SAH.

The authors did not distinguish between SAH where an aneurysm was identified vs SAH where no aneurysm was found. This would have been useful as previous studies have indicated that aspirin may protect against aneurysm rupture. In addition, the highest risk of ICH was found in the short-duration group of warfarin users. This may be due to maintaining a balanced control of anticoagulation at the beginning of the treatment. Similar risk has been observed in recent trials comparing rivaroxaban to warfarin. It would be interesting to evaluate some characteristics of the patients' international normalized ratio trend—age or concomitant hypertension—to verify other predisposing factors vs the HAS-BLED score.

The addition of an antiplatelet to warfarin does not increase the risk of ICH vs users taking only warfarin. Adding antiplatelets in patients taking warfarin and affected by acute ischemic events might be beneficial by reducing the risk of further thrombotic episodes without the increase in cerebral bleeding risk. In this cohort study, it could be interesting also to identify characteristics (i.e., demographics and vascular risk factors) of patients with ICH treated with antiplatelets and warfarin to detect a risk profile for cerebral hemorrhage.

Finally, in this population-based study, the dual antiplatelet therapy (clopidogrel and aspirin) did not increase the risk of ICH significantly, which conflicts with previous clinical studies. This finding demonstrates that the "real world" might be better in results than the "trial world." © 2014 American Academy of Neurology


